Simon A Joosse
Overview
Explore the profile of Simon A Joosse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bayraktar R, Tang Y, Dragomir M, Ivan C, Peng X, Fabris L, et al.
Sci Adv
. 2025 Feb;
11(8):eado2830.
PMID: 39970212
The mutational landscape of phylogenetically ultraconserved elements (UCEs), especially those in noncoding DNAs (ncUCEs), and their functional relevance in cancers remain poorly characterized. Here, we perform a systematic analysis of...
2.
Rzhevskiy A, Sagitova G, Karashaeva T, Morozov A, Fatyanova A, Kazantseva V, et al.
Crit Rev Oncol Hematol
. 2024 Nov;
206:104579.
PMID: 39615710
The application of circulating tumor cells (CTCs) as diagnostic and prognostic markers in oncology is gaining increasing importance in clinical practice. Currently, various methods exist for detecting CTCs in patients'...
3.
Muhs S, Paraschiakos T, Schafer P, Joosse S, Windhorst S
Cells
. 2024 Aug;
13(16).
PMID: 39195269
Centrosomal Protein 55 (CEP55) exhibits various oncogenic activities; it regulates the PI3K-Akt-pathway, midbody abscission, and chromosomal instability (CIN) in cancer cells. Here, we analyzed the mechanism of how CEP55 controls...
4.
Dyshlovoy S, Paigin S, Afflerbach A, Lobermeyer A, Werner S, Schuller U, et al.
Int J Cancer
. 2024 Jul;
155(12):2129-2140.
PMID: 39031959
Oxford Nanopore Technologies sequencing, also referred to as Nanopore sequencing, stands at the forefront of a revolution in clinical genetics, offering the potential for rapid, long read, and real-time DNA...
5.
Bremer S, Boxnick A, Glau L, Biermann D, Joosse S, Thiele F, et al.
J Clin Immunol
. 2024 Feb;
44(3):69.
PMID: 38393459
Congenital heart disease (CHD) is the most common birth defect, and up to 50% of infants with CHD require cardiovascular surgery early in life. Current clinical practice often involves thymus...
6.
Rzhevskiy A, Kapitannikova A, Butnaru D, Shpot E, Joosse S, Zvyagin A, et al.
Biomedicines
. 2022 Dec;
10(12).
PMID: 36551871
Currently, sensitive and specific methods for the detection and prognosis of early stage PCa are lacking. To establish the diagnosis and further identify an appropriate treatment strategy, prostate specific antigen...
7.
8.
Joosse S, Pantel K
Cancer Res
. 2022 Jun;
82(12):2213-2215.
PMID: 35702889
Forty-five years ago, Cancer Research published the study by Leon and colleagues in which the authors described the observation of increased levels of cell-free DNA (cfDNA) in the serum of...
9.
Ningsi R, Elazezy M, Stegat L, Laakmann E, Peine S, Riethdorf S, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681601
CTCs have increasingly been used as a liquid biopsy analyte to obtain real-time information on the tumor through minimally invasive blood analyses. CTCs allow for the identification of proteins relevant...
10.
Prieske K, Alawi M, Jaeger A, Wankner M, Eylmann K, Reuter S, et al.
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944992
To date, therapeutic strategies in vulvar squamous cell carcinoma (VSCC) are lacking molecular pathological information and targeted therapy hasn't been approved in the treatment of VSCC, yet. Two etiological pathways...